Filing Details

Accession Number:
0001567619-21-019740
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-11-10 17:31:41
Reporting Period:
2021-11-08
Accepted Time:
2021-11-10 17:31:41
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
874716 Idexx Laboratories Inc IDXX In Vitro & In Vivo Diagnostic Substances (2835) 010393723
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1219445 P Brian Mckeon One Idexx Drive
Westbrook ME 04092
Executive Vp & Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-11-08 10,000 $67.85 36,317 No 4 M Direct
Common Stock Disposition 2021-11-08 1,300 $625.25 35,017 No 4 S Direct
Common Stock Disposition 2021-11-08 1,100 $626.47 33,917 No 4 S Direct
Common Stock Disposition 2021-11-08 1,326 $627.41 32,591 No 4 S Direct
Common Stock Disposition 2021-11-08 2,356 $628.19 30,235 No 4 S Direct
Common Stock Disposition 2021-11-08 2,094 $629.63 28,141 No 4 S Direct
Common Stock Disposition 2021-11-08 971 $630.39 27,170 No 4 S Direct
Common Stock Disposition 2021-11-08 743 $631.39 26,427 No 4 S Direct
Common Stock Disposition 2021-11-08 110 $632.19 26,317 No 4 S Direct
Common Stock Acquisiton 2021-11-09 6,310 $67.85 32,627 No 4 M Direct
Common Stock Disposition 2021-11-09 5,703 $630.13 26,924 No 4 S Direct
Common Stock Disposition 2021-11-09 607 $631.01 26,317 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right-to-buy) Disposition 2021-11-08 10,000 $0.00 10,000 $67.85
Common Stock Non-Qualified Stock Option (right-to-buy) Disposition 2021-11-09 6,310 $0.00 6,310 $67.85
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
35,535 2026-02-13 No 4 M Direct
29,225 2026-02-13 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 18,050 Indirect by Estony McKeon Family, LLC
Footnotes
  1. Includes 9 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2021.
  2. This transaction was executed in multiple trades at prices ranging from $625.00 to $625.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. This transaction was executed in multiple trades at prices ranging from $626.10 to $627.005. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. This transaction was executed in multiple trades at prices ranging from $627.07 to $628.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  5. This transaction was executed in multiple trades at prices ranging from $628.01 to $628.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  6. This transaction was executed in multiple trades at prices ranging from $629.10 to $629.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  7. This transaction was executed in multiple trades at prices ranging from $630.03 to $630.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  8. This transaction was executed in multiple trades at prices ranging from $631.10 to $631.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  9. This transaction was executed in multiple trades at prices ranging from $632.01 to $632.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  10. This transaction was executed in multiple trades at prices ranging from $630.00 to $631.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  11. This transaction was executed in multiple trades at prices ranging from $631.005 to $631.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  12. Grant of option to buy 45,535 shares of IDEXX Laboratories, Inc. common stock that vested in five annual installments beginning February 14, 2017.
  13. Not applicable.